Immatics NV (Immatics NV) Debt-to-Revenue : 0.12 (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Immatics NV Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Immatics NV's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $3.00 Mil. Immatics NV's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $12.91 Mil. Immatics NV's annualized Revenue for the quarter that ended in Mar. 2024 was $131.60 Mil. Immatics NV's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 0.12.

Immatics NV Debt-to-Revenue Historical Data

The historical data trend for Immatics NV's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immatics NV Debt-to-Revenue Chart

Immatics NV Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

Get a 7-Day Free Trial

0.18

0.20

0.28

0.08

0.29

Immatics NV Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Revenue	Get a 7-Day Free Trial															0.38	0.19	0.69	0.24	0.12

Competitive Comparison of Immatics NV's Debt-to-Revenue

For the Biotechnology subindustry, Immatics NV's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immatics NV's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immatics NV's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Immatics NV's Debt-to-Revenue falls into.

Immatics NV Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Immatics NV's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(2.84	+	13.956)	/	58.884
	=	0.29

Immatics NV's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(3.002	+	12.91)	/	131.604
	=	0.12

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.

Immatics NV Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Immatics NV's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Immatics NV (Immatics NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immatics NV (NAS:IMTX) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

4A3:Germany

Address

Paul-Ehrlich-Strasse 15, Tubingen, BW, DEU, 72076

Website

https://www.immatics.com

Immatics NV is a biotechnology company that is engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.